New drug cocktail aims to tame deadly bile duct cancer
NCT ID NCT07619235
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two immunotherapy drugs (iparomlimab and toripalimab) plus bevacizumab and chemotherapy as a first treatment for advanced biliary tract cancer. It involves 32 adults aged 18-75 who have not had prior treatment for their advanced cancer. The goal is to see if this combo can control the disease and improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a vaccine help fight Hard-to-Treat cancers?
- A new test could reveal how radiation affects the liver
- Can matching cancer drugs to tumor genes prevent biliary tract cancer return?
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- Can a smart drug home in on Hard-to-Treat GI cancers?
- Can a dual immune booster plus chemo shrink hard-to-treat bile duct tumors?